Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

Status:	Archived
Conditions:	Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	Any
Updated:	7/1/2011
Start Date:	July 2010
End Date:	January 2012

A Multi-center, Open-Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

This study provides a mechanism for continued administration of ALN-VSP02 therapy to
patients with cancer who completed participation in another ALN-VSP02 clinical study. The
primary objective of this study is to collect long term safety data.

Study ALN-VSP02 is an extension study for previously conducted ALN-VSP02 studies. The study
is being conducted to allow for continued ALN-VSP02 therapy for patients who completed
participation in an ALN-VSP02 clinical study, achieved clinical benefit with ALN-VSP02
(i.e., disease response of stable disease or better), and, in the Investigator's opinion,
may benefit from continuation of ALN-VSP02 therapy.

We found this trial at

sites

Sarah Cannon Cancer Center

230 25th Ave N
Nashville, Tennessee 37203

(615) 329-7274